Supportive Care Is Not the Only
Option in Prostate Cancer Patients
Resistant to Hormone Therapy:
The Argument Against

Jewett, Michael A.S.; Khakpour, Golnaz; Moore, Malcolm J.

doi:10.1159/000473839

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,18 Estimated median survival for patients with this disease is six to 12 months. 19 During this period, many patients experience moderate to severe disability due to bone metastases and require narcotic analgesics to achieve adequate pain control. 18 The use of chemotherapy to provide palliation to this patient population is controversial.…”

Section: Example Of the Evaluation Of Palliative Endpointsmentioning

confidence: 99%

Evaluation of Palliative Endpoints in Oncology Clinical Trials

Jacobsen

Weitzner

1999

Cancer Control

View full text Add to dashboard Cite

For patients with advanced cancer, the treatment goal of improving the quality of life may be as important as improving their quantity of life. Background: In recent years, there has been a growing recognition that improvements in quality of life may be as important as improvements in quantity of life in patients with advanced cancer. With this goal in mind, many oncology trials now seek to evaluate palliative endpoints as well as disease progression and survival. Methods: Methodologic advances and challenges in evaluating palliative endpoints in oncology clinical trials are reviewed. Results: Valid and reliable self-report measures have been developed that permit evaluation of palliative endpoints. Issues to consider in conducting research on palliative endpoints include the selection of appropriate outcome measures, the number and timing of outcome assessments, and the handling of missing data. Conclusions: The inclusion of palliative endpoints into clinical trials in oncology has the potential to advance clinical care by identifying chemotherapeutic agents that are effective in improving the quality of life of patients with advanced cancer.

show abstract

Section: Example Of the Evaluation Of Palliative Endpointsmentioning

confidence: 99%

Evaluation of Palliative Endpoints in Oncology Clinical Trials

Jacobsen

Weitzner

1999

Cancer Control

View full text Add to dashboard Cite

show abstract

“…New therapies are required for the treatment of prostate cancer; many patients have low‐volume residual disease after procedures such as radical prostatectomy [ 1] or radiotherapy [ 2] which were performed with curative intent. Androgen ablation is effective for only a limited time and no current therapy prolongs the survival of patients once the disease is hormone‐refractory [ 3]. Recent advances in the understanding of tumour immunology and the ability to perform gene transfer have lead to a resurgence of interest in tumour immunotherapy and cancer vaccines, even for non‐immunogenic tumours such as prostate cancer [ 4].…”

Section: Introductionmentioning

confidence: 99%

Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer

Hrouda

Souberbielle

Kayaga

et al. 1998

British Journal of Urology

View full text Add to dashboard Cite

Objective To evaluate the potential of heat-killed Results SRL172 was eCective as an adjuvant to autologous whole tumour cell vaccination in the prevention Mycobacterium vaccae (SRL172) as a nonspecific immunostimulant and as an adjuvant to whole tumour cell of MAT-LyLu tumours and the survival benefit was equivalent to that provided when the adjuvant was vaccination in the rat model of prostate cancer. Materials and methods SRL172 was used as a vaccine live-attenuated BCG. SRL172 alone did not reduce tumour take or tumour growth in this model and in the prevention and treatment of subcutaneous tumours in rats. Prevention experiments were conduc-neither strategy was eCective in delaying the growth of established MAT-LyLu tumours. In the Lobund-ted using subcutaneous MAT-LyLu tumours in Copenhagen rats, comparing vaccination with Wistar rat vaccination with autologous whole tumour cells and SRL172 significantly delayed the growth of SRL172 alone, SRL172 plus autologous cells, and bacille Calmette-Guèrin (BCG) plus autologous cells established tumours. Conclusion Mycobacterium vaccae deserves further evalu-before tumour implantation. Treatment experiments were conducted using subcutaneous MAT-LyLu ation as an adjuvant to whole tumour cell vaccination in a phase I clinical trial in patients with prostate tumours in the Copenhagen rat and subcutaneous PAIII tumours in the Lobund-Wistar rat. Tumours cancer. Keywords Prostate cancer, immunotherapy, Myco-were induced by subcutaneous injection with tumour cells. Animals were then vaccinated with autologous bacterium vaccae, vaccine, rat model cells, autologous cells plus SRL172, or SRL172 alone. or by the co-injection of adjuvant [5]. In animal models

show abstract

Supportive Care, Pain Management, and Quality of Life in Advanced Prostate Cancer

Esper¹,

Redman²

1999

Urologic Clinics of North America

View full text Add to dashboard Cite

Supportive Care Is Not the Only Option in Prostate Cancer Patients Resistant to Hormone Therapy: The Argument Against

Cited by 4 publications

References 6 publications

Evaluation of Palliative Endpoints in Oncology Clinical Trials

Evaluation of Palliative Endpoints in Oncology Clinical Trials

Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer

Supportive Care, Pain Management, and Quality of Life in Advanced Prostate Cancer

Contact Info

Product

Resources

About